) revealed that the American College of Chest Physicians (ACCP)
has included the company's superDimension Electromagnetic
Navigation Bronchoscopy (ENB) system in its guidelines for early
detection and diagnosis of lung cancer.
With hardly any signs of symptoms at an early stage, lung cancer
usually goes undetected for a prolonged period of time. This
makes lung cancer the leading cause of death in the U.S. Lung
cancer, if detected and treated at an early stage, can
significantly increase long-term survival rate.
The one-of-a-kind ENB system is an effective and safe diagnostic
platform for early detection of lung cancer. It became part of
Covidien's Endomechanical product portfolio with the acquisition
of superDimension in 2012. The advanced technology of the system
can access difficult areas of the lungs to collect tissue sample
of lesions, which is usually unattainable by conventional
bronchoscopes. Moreover, its minimally invasive technology is
less morbid in comparison to more invasive procedures.
Covidien is a leading global health care products company with a
history of developing high-quality products in a cost-effective
manner. The incorporation of the ENB system in the ACCP
guidelines further reinstates this commitment by the company.
However, the company recently provided a dismal fiscal 2013
guidance, which complements its Zacks Rank #5 (Strong Sell).
Further, uncertainty regarding divestment of the Pharmaceutical
unit at the end of Jun 2013 keeps us on the sidelines.
While we strongly recommend investors to avoid this stock, other
medical stocks such as
) warrant a look. All the stocks carry a Zacks Rank #2 (Buy).
ATRICURE INC (ATRC): Free Stock Analysis
COVIDIEN PLC (COV): Free Stock Analysis
CONCEPTUS INC (CPTS): Free Stock Analysis
MYRIAD GENETICS (MYGN): Free Stock Analysis
To read this article on Zacks.com click here.